Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $24.75 USD
Change Today -0.19 / -0.76%
Volume 443.3K
GMED On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

globus medical inc - a (GMED) Key Developments

Globus Medical, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Increases Earnings Guidance for the Year 2015

Globus Medical, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net income of $24.05 million or $0.25 per diluted share on sales of $133.6 million compared to net income of $20.6 million or $0.22 per diluted share on sales of $113.6 million reported in the same period last year. Operating income was $37.0 million against $31.55 million reported last year. Income before income taxes was $37.5 million against $31.9 million reported last year. EBITDA was $43.1 million against $37.1 million reported last year. Adjusted EBITDA was $46.7 million against $40.15 million reported last year. Non-GAAP net income was $24.3 million or $0.25 per diluted share against $21.5 million or $0.23 per diluted share reported last year. For the six months, the company reported net income of $48.7 million or $0.51 per diluted share on sales of $265.2 million compared to net income of $41.8 million or $0.44 per diluted share on sales of $227.8 million reported in the same period last year. Operating income was $75.55 million against $63.8 million reported last year. Income before income taxes was $75.6 million against $64.4 million reported last year. Net cash provided by operating activities was $47.8 million against $41.6 million reported last year. Purchases of property and equipment was $25.1 million against $12.2 million reported last year. EBITDA was $86.7 million against $74.65 million reported last year. Adjusted EBITDA was $93.1 million against $82.2 million reported last year. Non-GAAP net income was $49 million or $0.51 per diluted share against $44.3 million or $0.46 per diluted share reported last year. The company increased guidance on sales by $10 million to $524 million and earnings per share by $0.02 to $1.04.

Globus Medical, Inc. to Report Q2, 2015 Results on Jul 30, 2015

Globus Medical, Inc. announced that they will report Q2, 2015 results at 5:30 PM, Eastern Daylight on Jul 30, 2015

Globus Medical, Inc., Q2 2015 Earnings Call, Jul 30, 2015

Globus Medical, Inc., Q2 2015 Earnings Call, Jul 30, 2015

Globus Medical, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 04:00 PM

Globus Medical, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 04:00 PM. Venue: InterContinental Boston, 510 Atlantic Avenue, Boston, MA 02210, United States.

Globus Medical, Inc. Announces RISE-L, an Expandable Lateral Interbody Fusion Devicec

Globus Medical, Inc. announced the introduction of RISE®-L, a lateral lumbar interbody fusion (LLIF) device and the latest addition to the company’s portfolio of expandable spacers. The LLIF procedure, approaching the spine from the side of the patient, allows for a larger implant footprint, and is less disruptive to lower back muscles as compared other approaches, which may result in less blood loss and faster recovery. RISE®-L is a vertically expanding LLIF device designed to minimize impaction, maximize indirect decompression, and provide a large graft space optimal for fusion potential. The all-titanium implant is designed for up to 7mm of continuous in situ expansion and to provide restorative disc height with proper anatomical fit. Available in multiple sizes, in parallel or lordotic profiles, RISE®-L provides options for surgeons to address proper sagittal balance. A large single graft chamber can be filled with autogenous bone graft material after insertion and expansion to ensure even contact with both vertebral endplates. Globus Medical has steadily innovated its lateral platform starting with the PATRIOT® TransContinental™ LLIF cage over six years ago by bringing to market several advanced treatment options including the CALIBER®-L expandable cage, InterContinental® plate-spacer, and PLYMOUTH® lateral plate. Each product can be used in conjunction with Globus Medical’s MARS™ and MARS™ 3V retractors.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GMED:US $24.75 USD -0.19

GMED Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Integra LifeSciences Holdings Corp $60.79 USD +0.25
K2M Group Holdings Inc $21.65 USD +0.15
LDR Holding Corp $38.67 USD -0.27
NuVasive Inc $53.75 USD +1.00
Orthofix International NV $38.08 USD +0.70
View Industry Companies
 

Industry Analysis

GMED

Industry Average

Valuation GMED Industry Range
Price/Earnings 23.8x
Price/Sales 4.7x
Price/Book 3.7x
Price/Cash Flow 23.7x
TEV/Sales 4.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLOBUS MEDICAL INC - A, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.